Shots:
- Santhera enters into a collaboration with Biozentrum, University of Basel to explore the feasibility of the gene therapy by standard viral vectors for LAMA2 MD or MDC1A, co-financed by Innosuisse of ~$1.19M
- The focus of the collaboration is to foster Santhera’s neuromuscular pipeline and to utilize Biozentrum’s gene therapy in its Omigapil for improving its benefits in LAMA2 deficient MD
- Biozentrum’s gene therapy utilizes two linker proteins derived from agrin, laminin and nidogen leading to a restoration of muscle fiber, recovery of muscle force and size and increases body weight. Omigapil is a deprenyl-analog, exclusively licensed from Novartis by Santhera for CMD
Click here to read full press release/ article | Ref: Santhera | Image: Pinterest
